City
Epaper

Gene-based blood test may help predict early signs of cancer's return

By IANS | Updated: April 16, 2025 15:27 IST

New Delhi, April 16 Monitoring blood levels of DNA fragments shed by dying tumour cells may accurately predict ...

Open in App

New Delhi, April 16 Monitoring blood levels of DNA fragments shed by dying tumour cells may accurately predict cancer recurrence, according to a new study.

Researchers at New York University-Langone Health, US, focussed on nearly 600 men and women from Europe, North America, and Australia, with stage III melanoma -- among the most aggressive forms of skin cancer.

The study showed that approximately 80 per cent of skin cancer patients with detectable levels of circulating tumour DNA (ctDNA), before they started treatment to suppress their tumours, went on to experience recurrence.

The disease was also found to return more than four times faster in this group than in those with no detectable levels of the biomarker, and the higher their levels, the faster the cancer returned.

"Our findings suggest that circulating tumour DNA tests could help oncologists identify which melanoma patients are most likely to respond well to therapy," said study lead author Mahrukh Syeda, a research scientist at NYU Grossman School of Medicine.

"In the future, such assessments may be used routinely in the clinic to help guide treatment decisions," added Syeda.

In the study, published in the journal The Lancet Oncology, the team also found that nearly all of those with detectable levels of ctDNA at three, six, nine, or 12 months into treatment experienced melanoma recurrence.

As a result, the researchers said, if the gene fragments are not observable prior to therapy but appear later on, this could indicate that the disease might be worsening.

Syeda said that the ctDNA method works by focusing on the most common mutations in the genetic code in melanoma cells.

The mutated DNA spills into surrounding blood as the cells break down.

Further, the team showed that assessing ctDNA levels were as good or better at predicting recurrence than other experimental tests that examine a tumour itself, such as those that measure immune activity within a group of cancer cells.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

InternationalTravesty of justice: Bangladesh SC stays High Court order granting bail to Chinmoy Das

EntertainmentKaran Johar welcomes Rohit Saraf to the Dharma family

NationalUnion Minister Kumaraswamy terms Centre's Caste Census decision 'historic and visionary'

MumbaiDeven Bharti Takes Charge as Mumbai Police Commissioner; Post Returns to ADG Rank After 10 Years

InternationalSaudi Arabia expresses concern over "escalating tensions" between India, Pakistan; calls on both to de-escalate, work for stability & peace

Technology Realted Stories

Technology75 pc of Indian businesses localise data as AI becomes core to strategy: Report

TechnologyPunjab starts first-of-its-kind B.Tech programme

TechnologyDynamic curriculum, continuous evolution of training modules key to stay relevant: Jitendra Singh

TechnologySEBI reviewing derivatives rules to protect retail investors: Tuhin Kanta Pandey

TechnologyIndia’s GCCs record robust rise in women staffers at senior levels